These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332 [TBL] [Abstract][Full Text] [Related]
25. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab. Kosche C; Owen JL; Choi JN Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010 [TBL] [Abstract][Full Text] [Related]
26. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. Jones PS; Cahill DP; Brastianos PK; Flaherty KT; Curry WT Neurosurg Focus; 2015 Mar; 38(3):E5. PubMed ID: 25727227 [TBL] [Abstract][Full Text] [Related]
27. Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer. Naito T; Osaki M; Ubano M; Kanzaki M; Uesaka Y Neurol Sci; 2018 Oct; 39(10):1791-1793. PubMed ID: 29948463 [No Abstract] [Full Text] [Related]
28. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172 [TBL] [Abstract][Full Text] [Related]
29. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction. Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491 [TBL] [Abstract][Full Text] [Related]
30. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. van Bussel MTJ; Beijnen JH; Brandsma D BMC Cancer; 2019 May; 19(1):519. PubMed ID: 31146733 [TBL] [Abstract][Full Text] [Related]
31. [Endocrine side effects of checkpoint inhibitors]. Chen WJY; Krul-Poel YHM; Roth C; Labots M; van den Eertwegh AJM; Dreijerink KMA Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31714042 [TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Thibault C; Vano Y; Soulat G; Mirabel M Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497 [No Abstract] [Full Text] [Related]
40. Management of Brain Metastases in the New Era of Checkpoint Inhibition. Lauko A; Thapa B; Venur VA; Ahluwalia MS Curr Neurol Neurosci Rep; 2018 Aug; 18(10):70. PubMed ID: 30121715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]